MUC1 and pancreatic neoplasm: Next, using a standard 5-hr 51Cr-release assay, we evaluated the cytolytic activity of these CAR-modified cells against CAPAN1 pancreatic cancer cells, which express both target TAAs, albeit at different levels (PSCA – 95.1% and MUC1 – 68.5%; Figure 1C).